Purpuric Drug Eruptions Caused by Epidermal Growth Factor Receptor Inhibitors for Non–Small Cell Lung Cancer-Reference-Cited by-同舟云学术

Purpuric Drug Eruptions Caused by Epidermal Growth Factor Receptor Inhibitors for Non–Small Cell Lung Cancer

Published:2017-09-01 Issue:9 Volume:153 Page:906
ISSN:2168-6068
Container-title:JAMA Dermatology
language:en
Short-container-title:JAMA Dermatol

Author:

Cho Yung-Tsu¹,Chen Kai-Lung¹,Sheen Yi-Shuan¹,Yang Che-Wen¹,Liau Jau-Yu²,Cheng Yu-Pin³,Chu Chia-Yu¹

Affiliation:

1. Department of Dermatology, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan

2. Department of Pathology, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan

3. Department of Dermatology, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan3Department of Dermatology, Cathay General Hospital, Taipei, Taiwan

Publisher

American Medical Association (AMA)

Subject

Dermatology

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Dacomitinib‐induzierte purpuriforme Arzneimittelreaktion mit IQGAP1‐Hochregulierung bei einer Patientin mit Adenokarzinom der Lunge;JDDG: Journal der Deutschen Dermatologischen Gesellschaft;2023-07

2. Dacomitinib‐induced purpuric drug eruptions associated with IQGAP1 upregulation in a patient with lung adenocarcinoma;JDDG: Journal der Deutschen Dermatologischen Gesellschaft;2023-05-09

3. Temporal shifts of the microbiome associated with antibiotic treatment of purpuric drug eruptions related to epidermal growth factor receptor inhibitors;Journal of the European Academy of Dermatology and Venereology;2022-10-19

4. Identifying the Patterns of Adverse Drug Responses of Cetuximab;Korean Journal of Clinical Pharmacy;2022-09-30

5. A new adverse drug reaction – pigmented purpuric dermatosis caused by osimertinib administration – a case report;International Journal of Dermatology;2022-05-14